Cognitive Neurology Unit Clinical Registry

Recruiting now

Conditions studied: Alzheimer Disease

In brief

A Prospective Comparative Study Of Monoclonal Antibodies For The Treatment Of Alzheimer's Disease

Key facts

Study ID

NCT05925621

Run by

Beth Israel Deaconess Medical Center

People needed

500

Starts

2023-07-16

Expected to finish

2028-06-01

Last updated by the study team

2026-04-13

Who can join

Age: 50 and older, up to 95. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• o Patient meets clinical criteria for mild cognitive impairment or early dementia from Alzheimer's disease
• Patient has evidence of cognitive impairment on neuropsychological testing
• Patient has not progressed to the moderate stage of dementia based on neuropsychological testing or clinical judgement
• Amyloid PET imaging and/or CSF analysis consistent with Alzheimer's disease
• Amyloid PET imaging positive
• CSF p-Tau/Abeta42 ration >0.023 and ABeta42 < 1027**
• 3T MRI in past 6 months
• Patient has a care partner
• Patient under the care of an appropriate BI-Lahey amyloid clinic
• Patient is on a stable medication regimen

You may not qualify if…

• o Recent stroke or suspected TIA in the past year
• Pregnancy
• Active autoimmune or immunological disease
• Systemic treatment with immunosuppressants, immunoglobulins, or monoclonal antibodies or their derivatives
• Bleeding disorder with Plts < 50,000 or INR > 1.5
• On warfarin, heparin, or DOAC
• On dual antiplatelet therapy
• Non Alzheimer disease cause of dementia/MCI
• ApoE e4 homozygote

Where it is running

• Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.